Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of LY3537021 for Chemotherapy-Induced Nausea and Vomiting in Adults With Malignant Disease
jRCT2051250152Phase 2Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2025
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in chemotherapy-induced nausea and vomiting (CINV) comparing LY3537021 + Antiemetic Therapies with Placebo + Antiemetic Therapies (2 arms). Primary endpoint: Proportion of Participants with a Complete Response in the Delayed Phase of CINV. Started Nov 2025; status: recruiting.
02
Drugs
LY3537021
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on jRCT2051250152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250152.